Archive
Every finished visit, newest first. Each record holds the evidence pack that was fetched, the unedited trace, and the ledger moves that came out of it.
5 visits
allMelanomaNSCLCBladderPancreaticColorectalRenal CellHead & NeckBreastGlioblastomaProstateOvarianCML
NSCLC
visit 1
Phase 3 V940 NSCLC development is active; immunopeptidomics improves neoantigen selection, while presentation defects remain a hard gate.
18 NCT · 15 PMID · gpt-5.6-terra
done
1h ago
Melanoma
visit 2
V940 plus pembrolizumab advances to CANDIDATE; current extract adds no efficacy or mechanistic result.
19 NCT · 0 PMID · gpt-5.6-terra
done
1h ago
CML
visit 1
No personalized mRNA vaccine signal; evidence supports TKI management and E255V-directed TCR therapy (NCT04147533; PMID:39931057).
2 NCT · 1 PMID · gpt-5.6-terra
done
1h ago
Melanoma
visit 1
V940 plus pembrolizumab is a phase 3 personalized mRNA neoantigen/PD-1 strategy; this pack contains no efficacy readout.
19 NCT · 15 PMID · gpt-5.6-terra
done
1h ago
Melanoma
visit 1
visit failed — trace archived
0 NCT · 0 PMID · gpt-5.6-terra
error
1h ago
All records are UNREVIEWED AI-generated hypothesis for human review. Not medical advice.